Three Months Post-Launch: PYFAESTHETIC’s Collost Native Collagen Surpasses 2,500 Treatments

JAKARTA, September 9, 2026 – PT Pyridam Farma Tbk (IDX: PYFA), through its dedicated aesthetics division, PYFAESTHETIC, has announced a highly successful market reception for its latest innovation, Collost. Within just three months of its Indonesian debut, this Native Collagen Type I product has been successfully administered in over 2,500 aesthetic procedures. This rapid adoption trajectory underscores a robust market entry and highlights the growing consumer appetite for advanced aesthetic solutions domestically.

This accelerated uptake aligns seamlessly with the dynamic expansion of Indonesia’s medical aesthetics and beauty sector. According to market data from Statista, the domestic Beauty & Personal Care industry is projected to exceed US$9 billion in revenue by 2026, maintaining a steady compound annual growth rate (CAGR) of 4.39%. This growth is largely driven by heightened consumer awareness surrounding skin health and a surging demand for minimally invasive procedures. Capitalizing on the escalating trend for regenerative therapies, Collost was strategically introduced as a Native Collagen Replacement Therapy, designed to optimize skin regeneration tailored to the specific clinical needs of Indonesian patients.

Wila Kharisma, Head of PYFAESTHETIC, noted that this early-stage milestone reflects the strong confidence aesthetic practitioners have placed in the company’s product pipeline. She emphasized that prioritizing evidence-based clinical education delivered through specialized workshops and certified training with international experts, has been instrumental in driving effective market penetration while upholding the highest standards of patient safety.

“We are thrilled to report that Collost has surpassed 2,500 treatments in its first quarter on the Indonesian market,” stated Kharisma. “For us, this milestone transcends mere metrics; it reflects genuine industry enthusiasm and a strong validation of our Native Collagen Type I approach. This success further motivates PYFAESTHETIC to deepen our engagement and educational outreach with aesthetic practitioners, ensuring Collost is leveraged optimally and accurately to meet patient needs.”

Positioned as PYFAESTHETIC’s flagship innovation in Regenerative Medicine, Collost is sourced from Russia and features an intact Triple Helix Collagen structure. It is engineered to restore tissue integrity, enhance skin elasticity, and accelerate cellular regeneration with precision and safety, operating on the core principles of Rebuild, Restore, and Renew.

Looking ahead, PYFAESTHETIC remains committed to advancing its educational initiatives and fostering strategic partnerships across the medical community. These ongoing efforts are geared toward broadening practitioner expertise in Native Collagen Type I applications, while simultaneously elevating the standards of Indonesia’s regenerative and aesthetic medicine industry to remain highly competitive on a global scale.

About PYFA

PT Pyridam Farma Tbk, also known as PYFA, is a public pharmaceutical company listed on the Indonesia Stock Exchange (Ticker: PYFA). PYFA operates several business units producing prescription medicines in various forms, including tablets, capsules, creams, and injections. PYFA also has several well-known subsidiaries, including PT Holi Pharma, PT Ethica Industri Farmasi, and Probiotec Multipack.